In Vivo Restoration of Myocardial Conduction with Carbon Nanotube Fibers

碳纳米管纤维体内心肌传导恢复

基本信息

  • 批准号:
    10254737
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary / Abstract This is an application for a VA Merit Award Research Grant for Dr. Mark McCauley, a physician-scientist and staff Cardiologist/Electrophysiologist at the Jesse Brown VA Medical Center in Chicago. This award will provide Dr. McCauley with the support necessary to validate carbon nanotube fibers (CNTf) as a biocompatible, electrically conductive substance able to enhance ventricular conduction in the heart. To achieve these goals, Dr. McCauley has assembled a team of Electrophysiologists (Drs. Avitall and Razavi) and Bioengineers (Drs. Pasquali, Avitall, and Perin), who are Consultants on this application. Reduced myocardial conduction velocity (MCV) is a significant contributor to lethal cardiac arrhythmias including monomorphic ventricular tachycardia (VT) and sudden cardiac death (SCD). Due to underlying traditional coronary disease risk factors, and military-related exposures such as PTSD and agent orange, Veterans are more susceptible to developing VT and SCD. Previously, restoration of native myocardial conduction has not been possible because of lack of a biocompatible material that combines strength, fatigue- resistance, conductibility, and low impedance to charge transfer properties. Recently, CNTf have been described that combine these properties into a manufactured suture-like material. Published and preliminary data from our laboratory suggest that CNTf are capable of transferring electrical charge between electroanatomically distinct areas of myocardium, such as across ventricular scar and the AV junction. Additionally, CNTf are biocompatible materials with a unique high capacitance, low impedance material/tissue interface. The central hypothesis is that CNTf have such a low tissue-material impedance, that source-sink mismatch between electroanatomically separated tissues is sufficiently reduced to facilitate trans-myocardial conduction within cardiac tissue. To test this hypothesis, three Specific Aims are proposed: Aim 1 – Assess whether CNTf reduce source-sink mismatch across ventricular scar; Aim 2 – Determine whether CNTf increase MCV across post-infarction ventricular scar and prevent VT; Aim 3 – Determine the conductive stability, tensile strength, and inflammatory response to long- term CNTf implants. The innovation of our project is that for the first time, we are able to bridge electrically separate tissues with CNTf to facilitate trans-myocardial transfer of electrical signal. Our expected outcome from completion of the proposed Aims is an enhanced understanding of the mechanisms underlying CNTf-based electrical conduction, and the development of strong pre-clinical data necessary for the future application of CNTf to reduce adverse cardiac events in Veterans.
项目摘要/摘要 这是一份为马克·麦考利博士申请退伍军人荣誉奖研究补助金的申请,他是一名内科科学家和 芝加哥杰西·布朗退伍军人医学中心的心脏病专家/电生理学家。该奖项将提供 McCauley博士拥有验证碳纳米管纤维(CNTF)作为生物相容性所必需的支持, 能够增强心脏中的心室传导的导电物质。为了实现这些目标, 麦考利博士组建了一个由电生理学家(Avitall博士和Razavi博士)和生物工程师(Dr.Razavi博士)组成的团队。 Pasqui、Avitall和Perin),他们是此应用程序的顾问。 心肌传导速度减慢是致命性心律失常的重要因素。 包括单形性室性心动过速(VT)和心脏性猝死(SCD)。由于潜在的 传统的冠心病风险因素,以及与军事相关的暴露,如创伤后应激障碍和橙剂, 退伍军人更容易发生室上性心动过速和SCD。以前,自然心肌的恢复 由于缺乏一种结合强度、疲劳的生物兼容材料,传导一直是不可能的。 电阻、导电性和低阻抗至电荷转移特性。最近,CNTF被描述为 将这些特性结合到一种人造缝合线状材料中。来自我们的已公布数据和初步数据 实验室研究表明,CNTF能够在不同解剖结构之间转移电荷 心肌区,如横跨室壁疤痕和房室交界处。此外,CNTF具有生物相容性 具有独特的高电容、低阻抗材料/组织界面的材料。中心假设是 CNTF具有如此低组织材料阻抗,在电子解剖学上 分离的组织被充分减少,以促进心脏组织内的跨心肌传导。为了测试 在这一假设下,提出了三个具体的目标:目标1-评估CNTF是否减少了源-汇失配 跨越脑室疤痕;目标2:确定CNTF是否增加了跨脑梗塞后脑室疤痕的MCV 和预防室性心动过速;目标3-测定长期和长期的传导稳定性、抗拉强度和炎症反应。 术语CNTF植入物。我们项目的创新之处在于,我们第一次能够使用电桥 用CNTF分离组织,以促进电信号的跨心肌传递。我们的预期结果来自 拟议目标的完成是对基于CNTF的基础机制的更好理解 电传导,以及未来CNTF应用所需的强大临床前数据的开发 以减少退伍军人的不良心脏事件。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark D McCauley其他文献

Targeting ryanodine receptors for anti-arrhythmic therapy
以雷诺丁受体为靶点的抗心律失常治疗
  • DOI:
    10.1038/aps.2011.44
  • 发表时间:
    2011-06-03
  • 期刊:
  • 影响因子:
    8.400
  • 作者:
    Mark D McCauley;Xander H T Wehrens
  • 通讯作者:
    Xander H T Wehrens

Mark D McCauley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark D McCauley', 18)}}的其他基金

In Vivo Restoration of Myocardial Conduction with Carbon Nanotube Fibers
碳纳米管纤维体内心肌传导恢复
  • 批准号:
    10664850
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
In Vivo Restoration of Myocardial Conduction with Carbon Nanotube Fibers
碳纳米管纤维体内心肌传导恢复
  • 批准号:
    10438661
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Myosin Light Chain Dephosphorylation by PPP1R12C Promotes Atrial Hypocontractility and Atrial Fibrillation
PPP1R12C 的肌球蛋白轻链去磷酸化促进心房收缩力和心房颤动
  • 批准号:
    10394886
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Myosin Light Chain Dephosphorylation by PPP1R12C Promotes Atrial Hypocontractility and Atrial Fibrillation
PPP1R12C 的肌球蛋白轻链去磷酸化促进心房收缩力和心房颤动
  • 批准号:
    10617642
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了